Brilliant post!

First 5386 Last

Share
Profile

Follow
Glitterati

10,340 Posts.

2810

02/12/22

18:57

Post #: 65126270
Share

Originally posted by Lukkus01: ↑

i can understand why some people here are getting a bit impatient with the lack of announcements but i think the issue is more due to the way the share price has been manipulated than a lack of perfomance by asn. its only been 1 month since the last notable ann which was the second resource upgrade. some people seem to give little credit so the significance of that ann because the share price didnt jump like they hoped, that is out of bbb's hands though and obviously the mkt had set high expectations. everyone was singing bbb's praises when he put out a spectacular run of announcements and the share price jumped by 200%. but bbb cant just pull announcements out of thin air and its important to note that we are now in a quieter period while we advance feed offtakes and finance etc but make no mistake there is plenty of work going on behind the scenes.

with that being said there are 2 announcements i think are overdue and need to be sorted asap.

- commencement of drilling on western areas
-appointment of additional management staff

im very keen to see asn grow the management team and hopefully we can secure high quality personnel, this is where asn has been lacking for too long and really should have been done 6 months ago then perhaps we could have gone down the road of govt funding but at the end of the day that would have been a nice to have not a necessity. its also important to keep in mind there will still be stiff competition for grants and they are spread across all battery raw materials so i think this is why asn didnt want invest so much time into this because it could potentially be for nothing.
funding isnt an issue and neither is the payack period.

but seriously if anyone can find a lithium company anywhere near as close as asn to construction with such strong fundamentals/no political constraints and such a low mkt cap i am very interested to hear about it! i dont think there is one on the asx though. just have a look at peer valuations of lithium companies that have funding,offtakes,permits and are in contruction and its pretty easy to see asn will have a very exciting 2023.

Expand

Brilliant post!

ASN Price at posting: 22.5¢ Sentiment: Buy Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

The iron ore comeback: Can it last?

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ZNC

Zenith's sale of Develin Creek delivers $975K cash, with shares up 13%

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

HAS

Hastings progressing Yangibana to production with lower costs

There are more pages in this discussion • 15,953 more messages in this thread...

First 5386 Last

Add ASN (ASX) to my watchlist

(20min delay)
Last 7.7¢		Change -0.001(1.28%)		Mkt cap ! $99.49M

Open	High	Low	Value	Volume
7.8¢	8.0¢	7.7¢	$494.4K	6.321M

Buyers (Bids)

No.	Vol.	Price($)
3	69288	7.7¢

Sellers (Offers)

Price($)	Vol.	No.
7.8¢	380000	1

View Market Depth

No.	Vol.	Price($)
3	69288	0.077
4	606006	0.076
10	749283	0.075
5	204026	0.074
4	291000	0.073

Price($)	Vol.	No.
0.078	380000	1
0.079	604001	4
0.080	1245053	5
0.081	976780	5
0.082	300000	1

Last trade - 16.10pm 30/09/2024 (20 minute delay)

ASN (ASX) Chart

Brilliant post!

The iron ore comeback: Can it last?

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Zenith's sale of Develin Creek delivers $975K cash, with shares up 13%

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Hastings progressing Yangibana to production with lower costs

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Brilliant post!

Top Stories

The iron ore comeback: Can it last?

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Zenith's sale of Develin Creek delivers $975K cash, with shares up 13%

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Hastings progressing Yangibana to production with lower costs

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News